Patent Challenge Hearing on Gilead Hepatitis C Drug Sofosbuvir Starts in India

New York/New Delhi—In proceedings that could have major implications for millions of people waiting for affordable access to a lifesaving hepatitis C drug, the Indian Patent Office this week began hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges $1,000 per pill in the US.Today’s hearings are in relation to a "patent opposition" filed by lawye